|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||125.12 - 126.14|
|52 Week Range||118.62 - 148.32|
|PE Ratio (TTM)||278.43|
|Earnings Date||Oct 16, 2018|
|Forward Dividend & Yield||3.60 (2.86%)|
|1y Target Est||143.20|
Allergan’s stock price has fallen nearly 28.4% over the last 12 months, but it’s risen ~7.5% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~17.7% over the next 12 months.
There have been over 50 component changes to the Dow's since 1896, and these three stocks could be the next to join the prestigious index.
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
As the initial wave of healthcare companies unveil quarterly results, here are three takeaways from earnings calls. 1. Drugmakers are rethinking pricing strategies After Pfizer Inc. earlier this month said it would defer price hikes, Novartis AG said Wednesday, July 18, it will not raise prices for the rest of the year.
A woman who claimed her cancer was caused by using Johnson & Johnson's (JNJ.N) baby powder for decades said she believes justice was served after a jury found the company should pay her and 21 other women $4.69 billion in damages. A St. Louis jury on July 12 concluded that J&J's talc-based products contained asbestos, causing the 22 women, six of whom have died, to develop ovarian cancer. J&J Chief Executive Alex Gorsky earlier this week expressed confidence that the jury decision will be overturned on appeal.
A woman who claimed her cancer was caused by using Johnson & Johnson's baby powder for decades said she believes justice was served after a jury found the company should pay her and 21 other women $4.69 billion in damages. A St. Louis jury on July 12 concluded that J&J's talc-based products contained asbestos, causing the 22 women, six of whom have died, to develop ovarian cancer. J&J Chief Executive Alex Gorsky earlier this week expressed confidence that the jury decision will be overturned on appeal.
UnitedHealth delivered an earnings beat, but its shares fell. Johnson & Johnson's stock took a strong jump on earnings, despite recent bad news from a jury.
AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.
Wall Street's just dinged two of them and rewarded the third -- but Motley Fool analysts take a longer view.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.
Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
The university and health care giant are creating a life sciences network hub called JPOD@Philadelphia at the Pennovation Center.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. Over the last one-month, outflows of investor capital in ETFs holding JNJ totaled $1.74 billion.
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.
Strong sales of Johnson & Johnson’s cancer drugs and other medicines helped boost the company’s revenue and earnings for the latest quarter, but the health-products giant’s U.S. consumer business continued to struggle. Sales in the pharmaceuticals unit rose 19.9% globally, the largest increase among J&J segments. Cancer-drug sales rose 42.2%, helped by big gains for the Zytiga prostate-cancer drug and Darzalex, a blood-cancer treatment. J&J’s pharmaceutical sales topped analysts’ expectations despite what executives said was a continued decline in average net U.S. pricing after discounts and rebates.